Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Katja Krauß"'
Autor:
Ulrike Nitz, Oleg Gluz, Hans H. Kreipe, Matthias Christgen, Sherko Kuemmel, Frederick L. Baehner, Steven Shak, Bahriye Aktas, Michael Braun, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Benno Nuding, Maren Darsow, Claudia Schumacher, Katja Krauss, Wolfram Malter, Marc Thill, Mathias Warm, Rachel Wuerstlein, Ronald E. Kates, Nadia Harbeck
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal grow
Externí odkaz:
https://doaj.org/article/115b004b52414ec081eca0fe5b0d1c40
Autor:
Betül Altunay, Andreas Goedicke, Oliver H. Winz, Fabian Hertel, Dirk von Mallek, Levente K. Meszaros, Gitasha Chand, Hans-Jürgen Biersack, Elmar Stickeler, Katja Krauss, Felix M. Mottaghy
Publikováno v:
European journal of nuclear medicine and molecular imaging 50(4), 1005-1013 (2022). doi:10.1007/s00259-022-06066-3
European Journal of Nuclear Medicine and Molecular Imaging, 50(4), 1005-1013. Springer, Cham
European Journal of Nuclear Medicine and Molecular Imaging, 50(4), 1005-1013. Springer, Cham
European journal of nuclear medicine and molecular imaging (2022). doi:10.1007/s00259-022-06066-3
Published by Springer-Verl., Heidelberg [u.a.]
Published by Springer-Verl., Heidelberg [u.a.]
Autor:
Nadia Harbeck, Ulrike Nitz, Hans Heinrich Kreipe, Friedrich Feuerhake, Cornelia Kolberg-Liedtke, Hua Ni, Ronald Kates, Christine zu Eulenburg, Enrico Pelz, Hans Holger Fischer, Andrea Stefek, Toralf Reimer, Helmut Forstbauer, Claudia Schumacher, Katja Krauss, Rachel Wuerstlein, Jochem Potenberg, Michael Braun, Doris Augustin, Eva-Maria Grischke, Sherko Kuemmel, Jenci Palatty, Matthias Christgen, Daniel Ulbrich-Gebauer, Claudia Biehl, Oleg Gluz, Monika Graeser
Supplementary Table 1 lists genes comprising the RNA expression signatures measured with the BC360 panel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e60314eda6d7136a291f05f0aa7b39c
https://doi.org/10.1158/1078-0432.22490620.v1
https://doi.org/10.1158/1078-0432.22490620.v1
Autor:
Nadia Harbeck, Ulrike Nitz, Hans Heinrich Kreipe, Friedrich Feuerhake, Cornelia Kolberg-Liedtke, Hua Ni, Ronald Kates, Christine zu Eulenburg, Enrico Pelz, Hans Holger Fischer, Andrea Stefek, Toralf Reimer, Helmut Forstbauer, Claudia Schumacher, Katja Krauss, Rachel Wuerstlein, Jochem Potenberg, Michael Braun, Doris Augustin, Eva-Maria Grischke, Sherko Kuemmel, Jenci Palatty, Matthias Christgen, Daniel Ulbrich-Gebauer, Claudia Biehl, Oleg Gluz, Monika Graeser
Supplementary Figure 3 shows association between RNA signatures and overall survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb83951221fbad8da3405291383ceb0
https://doi.org/10.1158/1078-0432.22490623
https://doi.org/10.1158/1078-0432.22490623
Autor:
Nadia Harbeck, Ulrike Nitz, Hans Heinrich Kreipe, Friedrich Feuerhake, Cornelia Kolberg-Liedtke, Hua Ni, Ronald Kates, Christine zu Eulenburg, Enrico Pelz, Hans Holger Fischer, Andrea Stefek, Toralf Reimer, Helmut Forstbauer, Claudia Schumacher, Katja Krauss, Rachel Wuerstlein, Jochem Potenberg, Michael Braun, Doris Augustin, Eva-Maria Grischke, Sherko Kuemmel, Jenci Palatty, Matthias Christgen, Daniel Ulbrich-Gebauer, Claudia Biehl, Oleg Gluz, Monika Graeser
Purpose:To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) and survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452).Experimental Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ac3e075fb428952cc341942b7e5308
https://doi.org/10.1158/1078-0432.c.6533188
https://doi.org/10.1158/1078-0432.c.6533188
Publikováno v:
Urologie (Heidelberg, Germany)Literatur. 61(10)
Prostate and breast carcinomas are amongst the most common new diseases in men and women, with steadily rising incidences. In addition to the significant health consequences, both diseases also lead to a significantly reduced quality of life due to t
Autor:
Ulrike A. Nitz, Oleg Gluz, Sherko Kümmel, Matthias Christgen, Michael Braun, Bahriye Aktas, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Maren Darsow, Katja Krauss, Benno Nuding, Marc Thill, Jochem Potenberg, Christoph Uleer, Mathias Warm, Hans Holger Fischer, Wolfram Malter, Michael Hauptmann, Ronald E. Kates, Monika Gräser, Rachel Würstlein, Steven Shak, Frederick Baehner, Hans H. Kreipe, Nadia Harbeck
PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206 ; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ed8e287474cea9351d10c4db33aa369
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85129370895
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85129370895
Autor:
Oleg Gluz, Matthias Christgen, Sherko Kuemmel, Christine zu Eulenburg, Michael Braun, Bahriye Aktas, Kerstin Luedtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Katja Krauss, Marc Thill, Mathias Warm, Monika Karla Graeser, Rachel Wuerstlein, Ronald E. Kates, Frederick L. Baehner, Ulrike Nitz, Hans Heinrich Kreipe, Nadia Harbeck
Publikováno v:
Journal of Clinical Oncology. 40:536-536
536 Background: We evaluated concordance of ER, PR and HER2 status between local, central, and RT-PCR/mRNA assessments and its clinical impact in the ADAPT trial collective in HR+ HER2- EBC (NCT01779206). Particularly, validity of borderline ER-posit
Autor:
Wolfram Malter, Eva-Maria Grischke, Claudia Schumacher, Ulrike Nitz, Benno Nuding, Mathias Warm, Oleg Gluz, Helmut Forstbauer, Hans Kreipe, Sherko Kuemmel, Katja Krauss, Kerstin Lüdtke-Heckenkamp, Steven Shak, Bahriye Aktas, Frederick L. Baehner, Ronald E. Kates, Nadia Harbeck, Matthias Christgen, Maren Darsow, Rachel Wuerstlein, Michael Braun, Marc Thill
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human epidermal grow
Autor:
Elmar Stickeler, Katja Krauss
Publikováno v:
Breast Care (Basel)
Background: Endocrine therapy with a standard duration of 5 years is well known as an effective treatment for endocrine-sensitive breast cancer. Summary: In the adjuvant setting this treatment reduces the 15-year mortality rates by about 30 and 40% w